(0.50%) 5 043.71 points
(0.50%) 38 095 points
(0.95%) 15 754 points
(0.11%) $79.09
(5.43%) $2.04
(-0.04%) $2 310.00
(0.33%) $26.84
(0.90%) $963.45
(0.01%) $0.933
(-0.15%) $11.01
(0.05%) $0.799
(-1.36%) $92.00
Live Chart Being Loaded With Signals
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs)...
Stats | |
---|---|
Šios dienos apimtis | 10.80M |
Vidutinė apimtis | 4.95M |
Rinkos kapitalizacija | 5.51B |
EPS | $0 ( 2024-02-28 ) |
Kita pelno data | ( $0 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -22.44 |
ATR14 | $0.517 (1.29%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-07-11 | Blumenkranz Mark S. | Sell | 32 088 | Common Stock |
2023-07-11 | Blumenkranz Mark S. | Sell | 7 500 | Restricted Stock Units |
2023-07-11 | Blumenkranz Mark S. | Sell | 31 000 | Stock Option (Right to Buy) |
2023-07-11 | Blumenkranz Mark S. | Sell | 15 500 | Stock Option (Right to Buy) |
2023-07-11 | Blumenkranz Mark S. | Sell | 23 186 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-97.75 |
Last 100 transactions |
Buy: 73 584 | Sell: 6 010 653 |
Tūris Koreliacija
Iveric Bio Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
APLS | 0.867 |
PT | 0.861 |
INZY | 0.859 |
BLPH | 0.856 |
IMRX | 0.852 |
LFST | 0.848 |
LNTH | 0.846 |
AFINP | 0.844 |
GEOS | 0.843 |
BMEA | 0.842 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
CFFN | -0.899 |
ONEM | -0.88 |
SASR | -0.871 |
PFBC | -0.87 |
PBFS | -0.864 |
WABC | -0.858 |
SLN | -0.856 |
ISTR | -0.851 |
CMBM | -0.849 |
DZSI | -0.847 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Iveric Bio Inc Koreliacija - Valiuta/Žaliavos
Iveric Bio Inc Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-1.450 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-1.450 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.120 |
FY | 2020 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.140 |
Financial Reports:
No articles found.
Iveric Bio Inc
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.